Abstract
In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Current Drug Targets
Title:Medical Therapy and Mucosal Healing
Volume: 13 Issue: 10
Author(s): Marc Ferrante and Gert Van Assche
Affiliation:
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Abstract: In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Export Options
About this article
Cite this article as:
Ferrante Marc and Van Assche Gert, Medical Therapy and Mucosal Healing, Current Drug Targets 2012; 13 (10) . https://dx.doi.org/10.2174/138945012802429679
DOI https://dx.doi.org/10.2174/138945012802429679 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Th1-mediated Pathology in Mouse Models of Human Disease is Ameliorated by Concurrent Th2 Responses to Parasite Antigens
Current Topics in Medicinal Chemistry Accelerated Partial Breast Irradiation- Pros and Cons
Reviews on Recent Clinical Trials In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Preparation and Applications of Room Temperature Ionic Liquids in Organic Synthesis: A Review on Recent Efforts
Current Green Chemistry Natural History of Ulcerative Colitis: Current Knowledge
Current Drug Targets Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example
Endocrine, Metabolic & Immune Disorders - Drug Targets A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology Endogenous Chemical Mediators in Anti-Inflammation and Pro-Resolution
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Natural Flora and Anticancer Regime: Milestones and Roadmap
Anti-Cancer Agents in Medicinal Chemistry NF-κB in Anti-Inflammatory Activity of Probiotics: An Update
Current Immunology Reviews (Discontinued) Subject Index to Volume 4
Current Topics in Medicinal Chemistry Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases
Current Pharmaceutical Design Regulation of Polymorphonuclear Leukocyte-Intestinal Epithelial Cell Interactions: Signalling Events and Potential Drug Targets
Current Signal Transduction Therapy Vitamin-D Receptor (VDR) Gene Polymorphisms (TaqI, FokI) in Turkish Patients with Hashimoto’s Thyroiditis: Relationship to the Levels of Vit-D and Cytokines
Endocrine, Metabolic & Immune Disorders - Drug Targets Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
Current Rheumatology Reviews